Medgenics Announces Results of 2013 Annual Meeting of Stockholders
May 01 2013 - 9:15AM
Business Wire
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
“Company” or “Medgenics”),, the developer of a novel technology for
the sustained production and delivery of therapeutic proteins in
patients using their own tissue, today announces that all
resolutions proposed at the Company’s Annual Meeting of
Stockholders held yesterday were duly passed.
Each of the current directors of the Company, Dr. Sol J. Barer,
Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr.
Joseph J. Grano, Jr., Mr. Joel S. Kanter, Dr. Stephen D. McMurray
and Dr. Andrew L. Pearlman, was reelected to the Board of
Directors.
Stockholders also approved an amendment of the Company’s Stock
Incentive Plan, increasing the number of shares authorized to be
issued under the plan by 1,700,000 shares.
Stockholders also approved, on an advisory basis, the
compensation of the executive officers of the Company.
Additionally, the option to request the stockholders to vote, on an
advisory basis, on executive compensation every three years
received the most votes cast.
Stockholders also ratified the appointment of Kost Forer Gabbay
& Kasierer, a member of Ernst & Young Global, to serve as
the Company's independent registered public accounting firm for the
year ended December 31, 2013.
Final voting tallies are subject to certification by the
Company's inspector of elections and will be included in the
Company's report, which is to be filed with the Securities and
Exchange Commission within the next week.
About Medgenics
Medgenics is developing and commercializing Biopump™, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis C and hemophilia.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024